BRPI0514466A - composto, composição, e, métodos de inibir a quinase 1 do ponto de controle em uma célula, de sensibilizar células, e de inibir a proliferação celular aberrante - Google Patents

composto, composição, e, métodos de inibir a quinase 1 do ponto de controle em uma célula, de sensibilizar células, e de inibir a proliferação celular aberrante

Info

Publication number
BRPI0514466A
BRPI0514466A BRPI0514466-3A BRPI0514466A BRPI0514466A BR PI0514466 A BRPI0514466 A BR PI0514466A BR PI0514466 A BRPI0514466 A BR PI0514466A BR PI0514466 A BRPI0514466 A BR PI0514466A
Authority
BR
Brazil
Prior art keywords
inhibiting
composition
methods
cell
control point
Prior art date
Application number
BRPI0514466-3A
Other languages
English (en)
Inventor
Francine S Farouz
Ryan Holcomb
Eugene Thorsett
John Joseph Gaudino
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of BRPI0514466A publication Critical patent/BRPI0514466A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTO, COMPOSIçãO, E, MéTODOS DE INIBIR A QUINASE 1 DO PONTO DE CONTROLE EM UMA CéLULA, DE SENSIBILIZAR CéLULAS, E DE INIBIR A PROLIFERAçãO CELULAR ABERRANTE Compostos de uréia substituídos por arila e heteroarila-úteis no tratamento de doenças e condições relacionadas com o dano ao DNA ou lesões na replicação de DNA são divulgados. Os métodos de fabricar os compostos e seu uso como agentes terapêuticos, por exemplo, no tratamento do câncer e outras doenças caracterizadas pelo defeito na replicação de DNA, segregação cromossómica ou divisão celular também são divulgados.
BRPI0514466-3A 2004-08-19 2005-08-18 composto, composição, e, métodos de inibir a quinase 1 do ponto de controle em uma célula, de sensibilizar células, e de inibir a proliferação celular aberrante BRPI0514466A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60296804P 2004-08-19 2004-08-19
PCT/US2005/029518 WO2006021002A2 (en) 2004-08-19 2005-08-18 Compounds useful for inhibiting chk1

Publications (1)

Publication Number Publication Date
BRPI0514466A true BRPI0514466A (pt) 2008-06-10

Family

ID=35744692

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514466-3A BRPI0514466A (pt) 2004-08-19 2005-08-18 composto, composição, e, métodos de inibir a quinase 1 do ponto de controle em uma célula, de sensibilizar células, e de inibir a proliferação celular aberrante

Country Status (10)

Country Link
US (1) US20080318974A1 (pt)
EP (1) EP1778648A2 (pt)
JP (1) JP2008510719A (pt)
KR (1) KR20070054205A (pt)
CN (1) CN101115727A (pt)
AU (1) AU2005272586A1 (pt)
BR (1) BRPI0514466A (pt)
CA (1) CA2577880A1 (pt)
MX (1) MX2007002040A (pt)
WO (1) WO2006021002A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
GB201119799D0 (en) 2011-11-16 2011-12-28 Sentinel Oncology Ltd Pharmaceutical compounds
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
EP3157916B1 (en) 2014-06-19 2018-12-12 ARIAD Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN104628659A (zh) * 2015-01-27 2015-05-20 广西师范大学 具有抗肿瘤作用的吡嗪-芳基脲衍生物及其制备方法与应用
AU2017207299B2 (en) * 2016-01-11 2023-09-21 Celator Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and RAD3-related protein (ATR)
PL3411036T3 (pl) 2016-02-04 2022-04-04 Pharmaengine, Inc. 3,5-dipodstawione pirazole przydatne jako inhibitory kinazy punktu kontrolnego 1 (chk1) oraz ich preparaty i zastosowanie
SG11201908788YA (en) 2017-03-31 2019-10-30 Seattle Genetics Inc Combinations of chk1- and wee1 - inhibitors
US11634424B2 (en) * 2019-11-29 2023-04-25 Medshine Discovery Inc. Diazaindole derivative and use thereof as CHK1 inhibitor
WO2021119236A1 (en) 2019-12-10 2021-06-17 Seagen Inc. Preparation of a chk1 inhibitor compound
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
GB202107932D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL254871A (pt) * 1959-08-14
CH503460A (de) * 1969-01-31 1970-11-13 Agripat Sa Verfahren zum antimikrobiellen Ausrüsten bzw. zum Schützen von Textilfasern gegen Mikroorganismen
US4071524A (en) * 1976-11-08 1978-01-31 Riker Laboratories, Inc. Derivatives of urea
BR9814375A (pt) * 1997-12-22 2002-05-21 Bayer Ag Inibição de raf cinase usando difenil uréias substituìdas simétricas e assimétricas
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
WO2003093297A2 (en) * 2002-05-03 2003-11-13 Exelixis, Inc. Protein kinase modulators and methods of use
JP2007519609A (ja) * 2003-09-17 2007-07-19 アイコス コーポレイション 細胞増殖を制御するためのｃｈｋ１インヒビターの使用
CN101006075A (zh) * 2004-06-25 2007-07-25 艾科斯有限公司 可用于抑制chk1的双芳基脲衍生物
BRPI0512891A (pt) * 2004-07-02 2008-04-15 Icos Corp composto e um sal ou pró-droga ou solvato farmaceuticamente aceitável do mesmo, composição, métodos de inibir a quinase 1 do ponto de verificação em uma célula, de sensibilizar células em um indivìduo que passa por um tratamento quimioterapêutico ou radioterapêutico para uma condição médica e de inibir a proliferação de célula aberrante, uso de um composto, e artigo de fabricação para o uso farmacêutico em humano

Also Published As

Publication number Publication date
JP2008510719A (ja) 2008-04-10
EP1778648A2 (en) 2007-05-02
CA2577880A1 (en) 2006-02-23
MX2007002040A (es) 2008-01-11
KR20070054205A (ko) 2007-05-28
US20080318974A1 (en) 2008-12-25
AU2005272586A1 (en) 2006-02-23
CN101115727A (zh) 2008-01-30
WO2006021002A3 (en) 2006-04-20
WO2006021002A2 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
BRPI0514466A (pt) composto, composição, e, métodos de inibir a quinase 1 do ponto de controle em uma célula, de sensibilizar células, e de inibir a proliferação celular aberrante
BRPI0512891A (pt) composto e um sal ou pró-droga ou solvato farmaceuticamente aceitável do mesmo, composição, métodos de inibir a quinase 1 do ponto de verificação em uma célula, de sensibilizar células em um indivìduo que passa por um tratamento quimioterapêutico ou radioterapêutico para uma condição médica e de inibir a proliferação de célula aberrante, uso de um composto, e artigo de fabricação para o uso farmacêutico em humano
CY1111590T1 (el) Αρυλ και ετεροαρυλ ουριας αναστολεις chk1 για χρηση ως ραδιοευαισθοποιητες και χημειοευαισθητοποιητες
BRPI0515482A (pt) derivados heterocìclicos e seus usos como agentes terapêuticos
NO20074944L (no) Heteroarylureaderivater anvendlige for inhibering av CHK1
BRPI0515477A (pt) derivados heterocìclicos bicìclicos e o uso dos mesmos como inibidores de estaroil-coa-desaturase (scd)
BRPI0513864A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, sua utilização e método para o tratamento e/ou profilaxia de enfermidades
BRPI0606324A2 (pt) derivados de purina agindo como agonistas de receptor de a2a
ATE430743T1 (de) Benzimidazolsubstituierte thiophenderivate, die auf ikk3 wirken
BRPI0416605A (pt) composto, processo para preparar um composto, uso de um composto, métodos de inibição da atividade de trk, de tratamento ou profilaxia de cáncer, e de produção de um efeito anti-proliferativo em um animal de sangue quente e composição farmacêutica
BR0312464A (pt) Inibidores de tirosina quinases
BRPI0515499A (pt) derivados de piridina para a inibição de estearoil-coa-desaturase humana
UY29149A1 (es) Tiazolil-dihidro-indazoles
BRPI0515488A (pt) derivados de heterocìclicos e seu uso como agentes terapêuticos
BRPI0809998B8 (pt) composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina quinase, seus usos, seus processos de preparação e composições farmacêuticas
BRPI0412343A (pt) derivados de piridazina e seu uso como agentes terapêuticos
BR0317455A (pt) Derivados de pirrol-pirazol substituìdos como inibidores de quinase
BRPI0606817A2 (pt) derivados de piridazina e seu uso como agentes terapêuticos
WO2006120573A3 (en) Heterocyclic n-oxides as hypoxic selective protein kinase inhibitors
BRPI0108841B8 (pt) derivado de pirimidina, processo para prepapar o mesmo, e composição farmacêutica
BRPI0517945A (pt) derivados de quinuclidina e seu uso como antagonistas de receptor muscarìnico m3
BR9807995A (pt) Derivados de 1,5-diidro-pirazol(3,4-d)-pirimidinona
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
BRPI0510409A (pt) heterociclos bicìclicos contendo nitrogênio como inibidores da aromatase
BRPI0407253A (pt) Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.